JP2023513220A5 - - Google Patents

Info

Publication number
JP2023513220A5
JP2023513220A5 JP2022548088A JP2022548088A JP2023513220A5 JP 2023513220 A5 JP2023513220 A5 JP 2023513220A5 JP 2022548088 A JP2022548088 A JP 2022548088A JP 2022548088 A JP2022548088 A JP 2022548088A JP 2023513220 A5 JP2023513220 A5 JP 2023513220A5
Authority
JP
Japan
Prior art keywords
composition according
amyloid
subject
therapeutically effective
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018023 external-priority patent/WO2021163613A1/en
Publication of JP2023513220A publication Critical patent/JP2023513220A/ja
Publication of JP2023513220A5 publication Critical patent/JP2023513220A5/ja
Priority to JP2025202377A priority Critical patent/JP2026041805A/ja
Pending legal-status Critical Current

Links

JP2022548088A 2020-02-13 2021-02-12 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法 Pending JP2023513220A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202377A JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976325P 2020-02-13 2020-02-13
US62/976,325 2020-02-13
PCT/US2021/018023 WO2021163613A1 (en) 2020-02-13 2021-02-12 Method of decreasing amyloid beta monomer levels in patients with cognitive decline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202377A Division JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Publications (2)

Publication Number Publication Date
JP2023513220A JP2023513220A (ja) 2023-03-30
JP2023513220A5 true JP2023513220A5 (https=) 2024-02-19

Family

ID=77292728

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548088A Pending JP2023513220A (ja) 2020-02-13 2021-02-12 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法
JP2025202377A Pending JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202377A Pending JP2026041805A (ja) 2020-02-13 2025-11-24 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法

Country Status (8)

Country Link
US (1) US20230098944A1 (https=)
EP (1) EP4103604A4 (https=)
JP (2) JP2023513220A (https=)
KR (1) KR20220142477A (https=)
CN (1) CN115397849A (https=)
AU (1) AU2021218735A1 (https=)
IL (1) IL295427A (https=)
WO (1) WO2021163613A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026030341A1 (en) * 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2692258C2 (ru) * 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
AU2019318888A1 (en) * 2018-08-07 2021-03-18 Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2023513220A5 (https=)
Erdes et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults
CN108721265B (zh) 通过给予秋水仙碱衍生物治疗或预防心血管事件
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
CN1116870C (zh) 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
JP2024170602A (ja) 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
EP3137087A1 (en) Estrogen combination for treatment of multiple sclerosis
JP2022533968A5 (https=)
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2024527023A5 (https=)
CN115397849A (zh) 减少患有认知衰退的患者中的β-淀粉样蛋白单体水平的方法
JP6436913B2 (ja) Ｌ−４−クロロキヌレニンの剤形及び治療的使用
JP2023549849A5 (https=)
EP3028704B1 (en) Combinations of methotrexate and simvastatin for use in the treatment of osteosarcoma
JP2019509296A (ja) 筋萎縮性側索硬化症を防止および／またはこれと戦うためのポリリジン化合物の多重錯化合物
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
TW202116297A (zh) 組合療法之方法、組成物與套組
JP2026021307A (ja) 神経疾患又は状態を治療するための新しい治療レジメン
CN106535924A (zh) 阿尔茨海默病(ad)的治疗和预防
JP2019517550A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
EP4209222A1 (en) Treatment and prevention of alzheimer's disease (ad)
RU2180591C2 (ru) Средство для лечения сексуальных дисфункций у мужчин
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
AU2024281828A1 (en) Treatment for amyotrophic lateral sclerosis (als)
WO2003020274A1 (en) Treatment of atopic dermatitis